Evidence map›Paper›PMID 33931725›Full record

ArticleLeukemia2021

Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted.

Abhishek A Mangaonkar, David M Swoboda, Terra L Lasho, Christy Finke, Rhett P Ketterling, Kaaren K Reichard, Eric Padron, Chetasi Talati, Mrinal M Patnaik

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Haematologica · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abhishek A MangaonkarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-2458-9887
David M SwobodaDivision of Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Terra L LashoDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Christy FinkeDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Rhett P KetterlingDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Kaaren K ReichardDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Eric PadronDivision of Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-4707-7916
Chetasi TalatiDivision of Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. patnaik.mrinal@mayo.edu.ORCID http://orcid.org/0000-0002-2246-213X
Mrinal M PatnaikDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-6998-662X

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
NCATS NIH HHS UL1 TR002377
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MutationAgedAged, 80 and overBiomarkers, TumorFemaleGenomicsHumansMaleMiddle AgedMyelodysplastic-Myeloproliferative DiseasesPrognosisRetrospective StudiesSurvival RateBiomarkers, Tumor

Identifiers

PMID33931725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.